Optimapharm–Copestake A: management, 202007– CEO

	Period	2020-07-21
	Organisation	Optimapharm d.d.
	Group	Optimapharm (Group)
	Organisation 2	NN (NO NAME)
	Group	OTHER
	Product	clinical research services
	Product 2	contract research (drugs)
	Person	Copestake, Andrew (Optimapharm 202007– CEO)

Optimapharm d.d.. (7/21/20). "Press Release: Optimapharm Appoints Dr. Andrew Copestake as Chief Executive Officer".

Optimapharm is pleased to announce that Dr. Andrew Copestake has been appointed Chief Executive Officer, effective 20 th July 2020. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors.

Andrew brings almost 30 years industry experience, having worked in large multinational pharmaceutical companies, global and regional contract research organizations, the biotech sector, as well as other service providers. He also brings a global approach, having gained international experience during appointments in the USA, Japan and throughout Europe. Andrew holds a PhD in Respiratory & Exercise Physiology from Loughborough University, UK and a Bachelor Degree (Hons) in Applied Biology from East London University, UK. He is also a Fellow of the Royal Society of Medicine.

Andrew’s appointment comes at an important inflexion point for Optimapharm. Following The Rohatyn Group’s investment in Optimapharm, announced in May 2020, Optimapharm is rapidly expanding the scale and breadth of its services to continue to build on its reputation for delivery excellence and a client-focused approach throughout Europe. Andrew will add a layer of seasoned leadership and experience running global full-service companies and is immediately focused on further developing Optimapharm’s service offering to capitalise on the current market opportunity in Europe.

In his new role, Andrew will work very closely with Dr. Gordana Greguric Cicak, Optimapharm’s founder, who will continue to lead Optimapharm’s operations as Chief Operating Officer. Gordana will maintain day-to-day responsibility for Optimapharm’s Clinical Operations, Clinical Project Management and Regulatory & Safety teams, ensuring industry-leading project delivery, quality outcomes whilst consistently exceeding client expectations.

With Andrew and Gordana at the helm, Optimapharm is uniquely placed to expand its customer base and operational capabilities, in-line with our vision to accelerate our development into the first-choice European CRO.

Record changed: 2020-11-20